Brotizolam

Brotizolam
Clinical data
Trade names	Lendormin
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N05CD09 (WHO) ;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); CA: Schedule IV; DE: Prescription only (Anlage III for higher doses); UK: Class C; US: Unscheduled; UN: Schedule IV;
Pharmacokinetic data
Bioavailability	48–95%
Metabolism	Hepatic
Elimination half-life	4.4 hours (range, 2.6–6.9 h)
Excretion	Renal
Identifiers
	IUPAC name 2-Bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine;
CAS Number	57801-81-7 ;
PubChem CID	2451;
DrugBank	DB09017 ;
ChemSpider	2357 ;
UNII	5XZM1R3DKF;
KEGG	D01744 ;
ChEMBL	ChEMBL32479 ;
CompTox Dashboard (EPA)	DTXSID0022692 ;
ECHA InfoCard	100.055.404
Chemical and physical data
Formula	C15H10BrClN4S
Molar mass	393.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClC1=CC=CC=C1C2=NCC3=NN=C(C)N3C4=C2C=C(Br)S4;
	InChI InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3 ; Key:UMSGKTJDUHERQW-UHFFFAOYSA-N ;
	(what is this?) (verify)

Brotizolam (marketed under brand name Lendormin) is a sedative-hypnotic thienotriazolodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to other short-acting hypnotic benzodiazepines such as triazolam or midazolam. It is used in the short-term treatment of severe insomnia. Brotizolam is a highly potent and short-acting hypnotic, with a typical dose ranging from 0.125 to 0.25 milligrams, which is rapidly eliminated with an average half-life of 4.4 hours (range 3.6–7.9 hours).

It was patented in 1974 and came into medical use in 1984. Brotizolam is not approved for sale in the UK, United States or Canada. It is approved for sale in the Netherlands, Germany, Spain, Belgium, Luxembourg, Austria, Portugal, Israel, Italy, Taiwan and Japan.